BNP Paribas Financial Markets
XTLB

BNP Paribas Financial Markets’s XTL Biopharmaceuticals XTLB Stock Holding History

BNP Paribas Financial Markets’s Portfolio XTLB Stock Details XTLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-75
Closed -$843 – 4224
2024
Q1 		$843 Hold
75
– – ﹤0.01% 3871
2023
Q4 		$303 Hold
75
– – ﹤0.01% 3910
2023
Q3 		$269 Buy
75
+25
+50% +$92 ﹤0.01% 3815
2023
Q2 		$200 Buy
+50
New +$245 ﹤0.01% 3827

Other funds holding XTLB

NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

BNP Paribas Financial Markets's XTLB Position: Q2 2024 in Review

BNP Paribas Financial Markets sold out of XTL Biopharmaceuticals (XTLB) in Q2 2024, closing a stake of 75 shares — an estimated $843 sold.

BNP Paribas Financial Markets first reported a position in XTLB in Q2 2023 and held it in 4 quarters. The position peaked at $843 in Q1 2024. 4 funds tracked by Wall St. Rank hold XTLB as of Q2 2024.

  • BNP Paribas Financial Markets reported no remaining XTL Biopharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 75 XTL Biopharmaceuticals shares in Q2 2024, an estimated $843.
  • BNP Paribas Financial Markets first reported a position in XTL Biopharmaceuticals in Q2 2023 and held it in 4 quarters.
  • BNP Paribas Financial Markets's XTL Biopharmaceuticals position peaked at $843 in Q1 2024.
  • 4 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q2 2024.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2024, filed 13 Aug 2024.